The Australian Benralizumab Registry (ABenRa) is a module of the Australasian Severe Asthma Registry (ASAR). It was developed to collect and report on data from people with severe refractory eosinophilic asthma who receive benralizumab (Fasenra) treatment:
- As part of the PBS subsidised Benralizumab treatment cycle, and the Pharmaceutical Benefits Scheme (PBS) Section 100 Special Authority Program,
or
- For treatment of severe refractory eosinophilic asthma outside of the PBS restrictions.
Patient enrolment
Patients enrolled in the ABenRA are assessed for eligibility at registration and followed up prospectively for at least 2 years – data collection every 6 months
For more information see the ASAR page or TAZANZ ASAR website
If you would like to register your interest or for further information about ABenRa/ASAR , contact the TSANZ registries team:
Email: registries@thoracic.org.au
Webpage: https://thoracic.org.au/research-and-awards/australasian-severe-asthma-registry-asar/
ASAR is supported by AstraZeneca, GlaxoSmithKline, Novartis and Sanofi.
